Logotipo del repositorio
Logotipo del repositorio
 

Psilocibina en el contexto oncológico: abordando la ansiedad y depresión en pacientes con cáncer.

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_f1cf
dc.contributor.advisorMartinez Banfi, Martha Luz
dc.contributor.authorVasquez Pantoja, Cesar
dc.date.accessioned2024-07-09T21:19:04Z
dc.date.available2024-07-09T21:19:04Z
dc.date.issued2024
dc.description.abstractLa ansiedad y la depresión son trastornos comunes en pacientes con cáncer, afectando adversamente su bienestar y pronóstico. La psilocibina, un compuesto psicoactivo de ciertos hongos, se presenta como un tratamiento prometedor. Esta revisión sintetiza la evidencia sobre la eficacia y seguridad de la psilocibina para la ansiedad y depresión en el contexto oncológico. Los estudios revisados indican que una sola dosis de psilocibina, acompañada de soporte psicológico, puede inducir mejoras rápidas y duraderas en la ansiedad, depresión, angustia existencial y calidad de vida. Un estudio aleatorizado controlado cruzado mostró reducciones en la ansiedad y depresión mantenidas durante 7 semanas con psilocibina en comparación con placebo. Además, una investigación observacional retrospectiva encontró disminuciones en estos síntomas que persistieron hasta 14 meses. La psilocibina también ha demostrado ser beneficiosa para el bienestar espiritual. En términos de seguridad, no se reportaron efectos adversos graves, secundarios significativos, ni dependencia. A pesar de estos hallazgos alentadores, y los resultados de la prueba aplicada a psiquiatras colombianos sobre sus percepciones acerca de la psilocibina, todos concuerdan en que se necesitan más estudios clínicos rigurosos y amplios para corroborar estos resultados. En resumen, aunque preliminares, los datos sugieren que la psilocibina tiene un potencial considerable como tratamiento seguro, efectivo y de larga duración para aliviar la ansiedad y depresión, mejorando así la calidad de vida de los pacientes con cáncer. Investigaciones futuras deberán confirmar su eficacia y mecanismos de acción. La psilocibina podría representar una opción terapéutica novedosa en la psico-oncología.spa
dc.description.abstractAnxiety and depression are common disorders in cancer patients, adversely affecting their well-being and prognosis. Psilocybin, a psychoactive compound from certain mushrooms, is presented as a promising treatment. This review synthesises the evidence on the efficacy and safety of psilocybin for anxiety and depression in the cancer setting. The studies reviewed indicate that a single dose of psilocybin, accompanied by psychological support, can induce rapid and lasting improvements in anxiety, depression, existential distress and quality of life. A randomised controlled crossover study showed reductions in anxiety and depression maintained for 7 weeks with psilocybin compared to placebo. In addition, retrospective observational research found decreases in these symptoms that persisted for up to 14 months. Psilocybin has also been shown to be beneficial for spiritual well-being. In terms of safety, no serious adverse effects, significant side effects, or dependence were reported. Despite these encouraging findings, and the results of testing Colombian psychiatrists on their perceptions of psilocybin, all agree that further rigorous and large clinical studies are needed to corroborate these results. In summary, although preliminary, the data suggest that psilocybin has considerable potential as a safe, effective and long-lasting treatment to alleviate anxiety and depression, thereby improving the quality of life of cancer patients. Future research should confirm its efficacy and mechanisms of action. Psilocybin could represent a novel therapeutic option in psycho-oncologyeng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/14811
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias Jurídicas y Socialesspa
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.subjectPsilocibinaspa
dc.subjectCáncerspa
dc.subjectDepresiónspa
dc.subjectAnsiedadspa
dc.subject.keywordsPsilocybineng
dc.subject.keywordsCancereng
dc.subject.keywordsDepressioneng
dc.subject.keywordsAnxietyeng
dc.titlePsilocibina en el contexto oncológico: abordando la ansiedad y depresión en pacientes con cáncer.spa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaTrabajo de grado - pregrado
dcterms.referencesAndersen, K. A. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. In Acta Psychiatrica Scandinavica (Vol. 143, Issue 2, pp. 101–118). Blackwell Publishing Ltd. https://doi.org/10.1111/acps.13249eng
dcterms.referencesBortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., Pavlidis, N., & Carvalho, A. F. (2017).eng
dcterms.referencesDepression in cancer: The many biobehavioral pathways driving tumor progression. In Cancer Treatment Reviews (Vol. 52, pp. 58–70). W.B. Saunders Ltd. https://doi.org/10.1016/j.ctrv.2016.11.004eng
dcterms.referencesDavis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of PsilocybinAssisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285eng
dcterms.referencesdos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. In Expert Review of Clinical Pharmacology (Vol. 11, Issue 9, pp. 889–902). Taylor and Francis Ltd. https://doi.org/10.1080/17512433.2018.1511424eng
dcterms.referencesFernández-Ríos, L. (n.d.). Standards for the preparation and writing of Psychology review articles 1. In International Journal of Clinical and Health Psychology (Vol. 9, Issue 2).eng
dcterms.referencesGeiger, H. A., Wurst, M. G., & Daniels, R. N. (2018). DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience, 9(10), 2438–2447. https://doi.org/10.1021/acschemneuro.8b00186eng
dcterms.referencesGoodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart- Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., … Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/nejmoa2206443eng
dcterms.referencesGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards,eng
dcterms.referencesB. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513eng
dcterms.referencesGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. https://doi.org/10.1007/s00213-011-2358-5eng
dcterms.referencesGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5eng
dcterms.referencesGrob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstad, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116eng
dcterms.referencesHan, X. B., Fang, Y. Q., Liu, S. X., Tan, Y., Hou, J. J., Zhao, L. J., Li, F., & Bush, E. (2021).eng
dcterms.referencesEfficacy of combined naikan and morita therapies on psychological distress and posttraumatic growth in Chinese patients with advanced cancer: A randomized controlled trial. Medicine (United States), 100(30), E26701. https://doi.org/10.1097/MD.0000000000026701eng
dcterms.referencesHearn, B. G., Brubaker, M. D., & Richardson, G. (2022). Counselors’ attitudes toward psychedelics and their use in therapy. Journal of Counseling and Development: JCD, 100(4), 364–373. https://doi.org/10.1002/jcad.12429eng
dcterms.referencesJames, E., Robertshaw, T. L., Hoskins, M., & Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. In Human Psychopharmacology (Vol. 35, Issue 5). John Wiley and Sons Ltd. https://doi.org/10.1002/hup.2742eng
dcterms.referencesKelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2022). The psychedelic renaissance: the next trip for psychiatry? In Irish Journal of Psychological Medicine (Vol. 39, Issue 4, pp. 335–339). Cambridge University Press. https://doi.org/10.1017/ipm.2019.39eng
dcterms.referencesLi, A. (2009). Analyses on the Rate and Epidemic Characteristics of Anxiety and Depression among Cancer Patients in Yangpu District in Shanghai. In Asian Pacific Journal of Cancer Prevention (Vol. 10).eng
dcterms.referencesLi, D., Li, Y., Bai, X., Wang, M., Yan, J., & Cao, Y. (2022). The Effects of Aromatherapy on Anxiety and Depression in People With Cancer: A Systematic Review and Meta- Analysis. In Frontiers in Public Health (Vol. 10). Frontiers Media S.A. https://doi.org/10.3389/fpubh.2022.853056eng
dcterms.referencesLi, L., Wang, L., Duan, Y., Xiao, P., Zhou, Y., Luo, X., Liu, X., Xie, J., & Cheng, A. S. K. (2023). Intelligent physical activity versus modified behavioral activation in adolescent and young adult cancer patients with psychological distress: A randomized, controlled pilot trial. Cancer Medicine, 12(2), 1935– 1948. https://doi.org/10.1002/cam4.5030eng
dcterms.referencesLima, M. P., Longatto-Filho, A., & Osório, F. L. (2016). Predictor variables and screening protocol for depressive and anxiety disorders in cancer outpatients. PLoS ONE, 11(3). https://doi.org/10.1371/journal.pone.0149421eng
dcterms.referencesLowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The therapeutic potential of psilocybin. In Molecules (Vol. 26, Issue 10). MDPI AG. https://doi.org/10.3390/molecules26102948eng
dcterms.referencesMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B., & Knudsen, G. M. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 44(7), 1328–1334. https://doi.org/10.1038/s41386-019-0324-9eng
dcterms.referencesMattsson, S., Alfonsson, S., Carlsson, M., Nygren, P., Olsson, E., & Johansson, B. (2013). Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer - A clinical trial protocol. BMC Cancer, 13. https://doi.org/10.1186/1471-2407-13-414eng
dcterms.referencesMurphy, K. M., Burns, J., & Victorson, D. (2021). Consider the Source: Examining Attrition Rates, Response Rates, and Preliminary Effects of eHealth Mindfulness Messages and Delivery Framing in a Randomized Trial with Young Adult Cancer Survivors. Journal of Adolescent and Young Adult Oncology, 10(3), 272–281. https://doi.org/10.1089/jayao.2020.0102eng
dcterms.referencesNational Cancer Institute. (2021). Estadísticas sobre el cáncer. Recuperado de https://www.cancer.gov/espanol/cancer/naturaleza/estadisticas#:~:text=Estad%C3%ADs ticas%20generales%3A%20carga%20que%20representa%20el%20c%C3%A1ncer%20 a,muertes%20por%20c%C3%A1ncer%20a%2016%2C4%20millones.%20M%C3%A1s %20elementos 1.spa
dcterms.referencesNichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478eng
dcterms.referencesNipp, R. D., El-Jawahri, A., Fishbein, J. N., Gallagher, E. R., Stagl, J. M., Park, E. R., Jackson, V. A., Pirl, W. F., Greer, J. A., & Temel, J. S. (2016). Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer. Annals of Oncology, 27(8), 1607–1612. https://doi.org/10.1093/annonc/mdw205eng
dcterms.referencesPearson, C., Siegel, J., & Gold, J. A. (2022). Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences, 434, 120096. https://doi.org/10.1016/j.jns.2021.120096eng
dcterms.referencesPereira, M., Moreira, C. S., Izdebski, P., Dias, A. C. P., Nogueira-Silva, C., & Pereira, M. G. (2022). How Does Hedonic Aroma Impact Long-Term Anxiety, Depression, and Quality of Life in Women with Breast Cancer? A Cross-Lagged Panel Model Analysis. International Journal of Environmental Research and Public Health, 19(15). https://doi.org/10.3390/ijerph19159260eng
dcterms.referencesPinquart, M., & Duberstein, P. R. (2010). Depression and cancer mortality: A meta-analysis. Psychological Medicine, 40(11), 1797–1810. https://doi.org/10.1017/S0033291709992285eng
dcterms.referencesMattsson, S., Alfonsson, S., Carlsson, M., Nygren, P., Olsson, E., & Johansson, B. (2013).eng
dcterms.referencesPlotnik, L., Gibbs, G., & Graham, T. (2022). Psilocybin Conspectus: Status, Production Methods, and Considerations. www.begellhouse.comeng
dcterms.referencesRodenbach, R. A., Althouse, A. D., Schenker, Y., Smith, T. J., Chu, E., White, D. B., Bakitas, M., & Arnold, R. M. (2021). Relationships Between Advanced Cancer Patients’ Worry About Dying and Illness Understanding, Treatment Preferences, and Advance Care Planning. Journal of Pain and Symptom Management, 61(4), 723-731.e1. https://doi.org/10.1016/j.jpainsymman.2020.09.004eng
dcterms.referencesRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512eng
dcterms.referencesSoqia, J., Al-shafie, M., Agha, L. Y., Alameer, M. B., Alhomsi, D., Saadoun, R., & Saifo, M. (2022). Depression, anxiety and related factors among Syrian breast cancer patients: a cross-sectional study. BMC Psychiatry, 22(1). https://doi.org/10.1186/s12888-022- 04469-yeng
dcterms.referencesTrevino, K. M., Stern, A., Hershkowitz, R., Kim, S. Y., Li, Y., Lachs, M., & Prigerson, H. G. (2021). Managing Anxiety from Cancer (MAC): A pilot randomized controlled trial of an anxiety intervention for older adults with cancer and their caregivers. Palliative and Supportive Care, 19(2), 135–145. https://doi.org/10.1017/S1478951521000286eng
dcterms.referencesTylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin - Summary of knowledge and new perspectives. In European Neuropsychopharmacology (Vol. 24, Issue 3, pp. 342–356). https://doi.org/10.1016/j.euroneuro.2013.12.006eng
dcterms.referencesWalker, J., Mulick, A., Magill, N., Symeonides, S., Gourley, C., Burke, K., Belot, A., Quartagno, M., Van Niekerk, M., Toynbee, M., Frost, C., & Sharpe, M. (2021). Major Depression and Survival in People with Cancer. Psychosomatic Medicine, 83(5), 410– 416. https://doi.org/10.1097/PSY.0000000000000942eng
dcterms.referencesWong, C. L., Li, C. K., Choi, K. C., So, W. K. W., Kwok, J. Y. Y., Cheung, Y. T., & Chan, C. W. H. (2021). Effects of immersive virtual reality for preventing and managing anxiety, nausea and vomiting among paediatric cancer patients receiving their first chemotherapy: A study protocol for an exploratory trial. PLoS ONE, 16(10 October). https://doi.org/10.1371/journal.pone.0258514eng
dcterms.referencesXie, L., Ng, D. Q., Heshmatipour, M., Acharya, M., Coluzzi, P., Guerrero, N., Lee, S., Malik, S., Parajuli, R., Stark, C., Tain, R., Zabokrtsky, K., Torno, L., & Chan, A. (2023). Electroacupuncture for the management of symptom clusters in cancer patients and survivors (EAST). BMC Complementary Medicine and Therapies, 23(1). https://doi.org/10.1186/s12906-023-03926-9eng
dcterms.referencesYeung, K. S., Hernandez, M., Mao, J. J., Haviland, I., & Gubili, J. (2018). Herbal medicine for depression and anxiety: A systematic review with assessment of potential psychooncologic relevance. In Phytotherapy Research (Vol. 32, Issue 5, pp. 865–891). John Wiley and Sons Ltd. https://doi.org/10.1002/ptr.603eng
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaPsicologíaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
518.52 KB
Formato:
Adobe Portable Document Format
Descargar
Miniatura
Nombre:
PDF_Resumen.pdf
Tamaño:
150.14 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Pregrado
Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca